Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Stergios Boussios
 -- 1484 2023-09-15 03:55:22 |
2 update references and layout
Rita Xu
 Meta information modification 1484 2023-09-15 04:13:27 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ghose, A.; Bolina, A.; Mahajan, I.; Raza, S.A.; Clarke, M.; Pal, A.; Sanchez, E.; Rallis, K.S.; Boussios, S. Hereditary Ovarian Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/49214 (accessed on 04 August 2024).
Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, et al. Hereditary Ovarian Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/49214. Accessed August 04, 2024.
Ghose, Aruni, Anita Bolina, Ishika Mahajan, Syed Ahmer Raza, Miranda Clarke, Abhinanda Pal, Elisabet Sanchez, Kathrine Sofia Rallis, Stergios Boussios. "Hereditary Ovarian Cancer" Encyclopedia, https://encyclopedia.pub/entry/49214 (accessed August 04, 2024).
Ghose, A., Bolina, A., Mahajan, I., Raza, S.A., Clarke, M., Pal, A., Sanchez, E., Rallis, K.S., & Boussios, S. (2023, September 15). Hereditary Ovarian Cancer. In Encyclopedia. https://encyclopedia.pub/entry/49214
Ghose, Aruni, et al. "Hereditary Ovarian Cancer." Encyclopedia. Web. 15 September, 2023.
Hereditary Ovarian Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijerph191912057

Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely affordable and accessible screening strategy to reduce mortality from OC is still ongoing. This coupled with the late-stage presentation and poor prognosis harbours significant health-economic implications. OC is also the most heritable of all cancers, with an estimated 25% of cases having a hereditary predisposition. Advancements in technology have detected multiple mutations, with the majority affecting the BRCA1 and/or BRCA2 genes. Women with BRCA mutations are at a significantly increased lifetime risk of developing OC, often presenting with a high-grade serous pathology, which is associated with higher mortality due to its aggressive characteristic.

ovarian cancer genetic testing BRCA risk-reducing surgery

1. Introduction

Globally, ovarian cancer (OC) is the eighth most common cancer among women and the eighteenth most common cancer overall [1]. With around 7500 new cases every year and 5% of cancer-related deaths, OC is the sixth most common cancer as well as sixth most common cancer-related death among women in the United Kingdom (UK) [2]. In the United States of America (USA), it is the fifth most common cancer-related death [3]. OC has a lifetime risk of 1 in 78 and probability of mortality of 1 in 108 [2][3]. Overall, OC is the most lethal gynaecological malignancy and is recognised as the “silent killer” due to late-stage diagnosis caused by asymptomatic progression [3].
Primary OC can be categorised into non-epithelial and epithelial, germ cell, and sex cord-stromal cancer, with epithelial being the most common. Non-epithelial accounts for approximately 10% of all OC and includes mainly germ cell tumours, sex cord-stromal tumours, and some extremely rare tumours [4][5]. Germ cell tumours are extremely rare in menopausal women yet reported in the literature [6]. Ovarian carcinosarcomas, accounting for only 1–4% of all OC, are composed of an epithelial as well as a sarcomatous component [7]. Epithelial OC can be histologically categorised further into serous, clear cell, endometrioid, mucinous, or undifferentiated variety [8]. Whilst the old line of thinking hypothesised that ovarian carcinogenesis arose from metaplasia of the ovarian surface epithelium into the various subtypes (serous, mucinous, clear cell, endometrioid, and transitional), a newer accepted theory by Kurman et al. provides a dualistic model [9]. This classifies OC into Type I, which consists of clearly described precursor lesions, and Type II, where precursor lesions are not clearly described, wherein cancer may arise de novo from the tubal/ovarian epithelium. Type I, consisting of low-grade serous, mucinous, endometrioid, clear cell, and transitional cell carcinomas, is typically more indolent and presents at an earlier stage. Type II, consisting of high-grade serous carcinomas, undifferentiated carcinomas, and carcinosarcomas, behaves in a more aggressive manner, is genetically unstable, and typically presents at a later stage. Type II tumours have a high frequency of TP53 mutations, whereas type I have specific mutations targeting cell signalling pathways, which in turn unsettle BRCA expression, namely KRAS, BRAF, ERBB2, CTNNB1, PTEN, PIK3CA, ARID1A, and PPP2R1A [9][10]. Serous papillary peritoneal cancer shares common molecular, histological, and clinical features with epithelial OC, mainly high-grade serous, which made it reasonable to manage the two entities similarly [11]. The recommended treatment of OC is radical surgery, followed by adjuvant chemotherapy. The therapeutic strategy of gestational OC depends on histology, stage, and gestational weeks [12]. As the proteome closely mirrors the dynamic state of cells, tissues. and organisms, proteomics has great potential to deliver clinically relevant biomarkers for OC diagnosis and treatment [13].
OC aetiology can be categorised into sporadic and hereditary. Approximately 23% of OC has a hereditary element, with the majority of those caused by defects within the BRCA DNA repair genes [14]. It is estimated that the lifetime risk of OC is 40–50% amongst BRCA1 mutation carriers and 20–30% in BRCA2 mutation carriers, which is significantly higher than the general population [15]. Several other genetic traits have been identified as risk factors for developing OC [14][16]. These genetic factors offer an opportunity for primary and secondary prevention strategies to reduce the risk of these high-risk individuals developing OC. Platinum compounds and poly (ADP-ribose) polymerase (PARP) inhibitors are currently the two main classes of drugs active against cancer cells, harbouring DNA damage response and repair gene alterations [17]. Genomic alterations in the DNA damage repair pathway are emerging as novel targets for treatment across different cancer types, especially OC, breast, and prostate cancer [18][19][20].
Given the lack of evidence to support screening in high-risk individuals, a preventative approach, usually in the form of surgery or chemoprevention, is the first line of management in these women [21][22][23][24][25][26][27][28][29]. Growing evidence suggests prevention strategies are both clinically and economically superior [30][31]. However, whilst most evidence applies to sporadic OC, individuals at risk of hereditary ovarian cancers (HOC) may benefit even more from targeted interventions, which may be even more cost-effective in this high-risk population [32][33].

2. Hereditary Ovarian Cancer (HOC)

HOC constitutes almost a quarter of all epithelial OC cases [34]. Family history is the strongest risk. First- and second-degree relatives with OC carry a 3.6- and 2.9-fold lifetime risk of developing OC, respectively [35].
HOC is also comprised of hereditary cancer syndromes (HCS), with mutations inherited in an autosomal dominant (AD) fashion leading to multiple primaries presenting at a young age. The two principal syndromes accounting for at least 20% of all epithelial OC are hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer syndrome (HNPCC) [36][37].
HBOC constitutes approximately 80% of HOC and 15% of epithelial OC cases [36]. Within HBOC, 65–85% of cases primarily stem from genomic mutations in BRCA1 and BRCA2 tumour-suppressor genes [38]. These encode proteins for homologous recombination (HR) to repair DNA double-strand breaks (DSB) for maintaining genomic stability. The prevalence in the UK for BRCA1 is thought to be 0.07–0.09% and for BRCA2 0.14–0.22% [39]. The lifetime risk for development and average age of onset of OC from BRCA1 and BRCA2 is 40% and 20% and 49 to 53 years and 55 to 58 years, respectively [36][40]. More than 15% of HBOC cases arise due to mutations concerning other predisposition genes including BARD1, BRIP1, CHEK2, MRE11A, MSH6, NBN, PALB2, RAD50, RAD51C, or TP53 (Figure 1). BARD1, BRIP1, PALB2, RAD50, RAD51C, NBN, and MRE11A gene mutations have been implicated in OC as part of the BRCA2/Fanconi anaemia signalling pathway in the event of nil BRCA1 and/or BRCA2 mutations. They constitute a significant portion of the DNA DSB repair machinery as well as next-generation sequencing (NGS)-based multigene panels [41]. The BARD1 gene showed one novel and three previously known genomic alterations in Ratajska et al.’s cohort of 255 unselected OC cases. These were almost nil in their control group, thus highlighting their pathogenic potential [42]. The BRIP1 mutation increases OC risk by 8-fold and decreases lifespan by almost four years [43]. The PALB2 gene mutation is prevalent in up to 4% of BRCA-negative HBOC cases. Yang et al. found a significant association between PALB2 pathogenic variants and OC (i.e., a relative risk of almost three) [44]. The RAD51C gene is prevalent in up to 2.9% of HBOC families negative for BRCA1 and/or BRCA2 mutations. Meindl et al. found six pathogenic variants in RAD51C among 1100 German families, yielding a relative risk of six for developing OC [45]. RAD50 and MRE11A are constituents of the MRE11 complex. Heikkinen et al. identified germline mutations in RAD50 and MRE11A among 151 HBOC families [46]. Meanwhile, Ramus et al. revealed that the prevalence of germline mutations of the NBN gene was very low (0.2%), hence not contributing significantly to OC risk [47]. In epithelial OC, DNA mismatch repair (MMR) deficiency is the second most common cause of HOC—only behind HR deficiency—accounting for 10–15% of HOC [48]. Furthermore, it has been reported that high mRNA levels of MSH6, MLH1, and PMS2 were associated with a prolonged overall survival in OC. That supports the potential positive prognostic value of MMR genes in OC patients treated with platinum-based chemotherapy.
Figure 1. The illustration shows distribution of gene mutations in ovarian cancer. (a) Proportion of sporadic (75%) and hereditary (25%) ovarian cancer cases. (b) Details of HOC. The inner circle shows the proportions contributed by HBOC and Lynch Syndrome. The outer circle demonstrates the divisions shared by prominent genetic mutations (BRCA1, BRCA2, TP53) and mutation groups (mismatch repair genes, double-strand-break repair genes) corresponding approximately to the syndromic association in the inner circle.
LS is the second commonest cause of HOC responsible for approximately 15% cases and 4% of epithelial OC cases [38]. It primarily involves colorectal cancer along with an increased frequency of extracolonic tumours, including endometrial, ovarian, urogenital, brain, renal, gastric, and biliary. The lifetime risk of developing OC with LS is approximately 8 to 12%, and the mean age of presentation is about 43 years. Mutations in MMR genes have been implicated in LS, namely MSH2 (38% cases), MLH1 (32%), PMS2 (15%), and MSH6 (15%) [49]. Grindedal et al. noted a 30-year OC survival of 71.5% in 144 MMR mutation carriers with OC, seemingly better than BRCA mutation survival [50].
Other rarer syndromes concerning HOC include Li–Fraumeni syndrome, Cowden syndrome, Peutz–Jeghers syndrome, diffuse gastric cancer syndrome, and neurofibromatosis type 1 syndrome. These arise primarily due to mutations in the TP53, PTEN, STK11, CDH1, and NF1 genes, respectively [51]. Figure 1 illustrates the inherited gene mutations in HOC.

References

  1. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Available online: https://gco.iarc.fr/today/online-analysis-table (accessed on 5 June 2022).
  2. Cancer Research UK. Ovarian Cancer Statistics. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer (accessed on 5 June 2022).
  3. American Cancer Society. Key Statistics for Ovarian Cancer. Available online: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html (accessed on 5 June 2022).
  4. Cheung, A.; Shah, S.; Parker, J.; Soor, P.; Limbu, A.; Sheriff, M.; Boussios, S. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? Int. J. Environ. Res. Public. Health 2022, 19, 1106.
  5. Boussios, S.; Moschetta, M.; Zarkavelis, G.; Papadaki, A.; Kefas, A.; Tatsi, K. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Crit. Rev. Oncol. Hematol. 2017, 120, 43–51.
  6. Boussios, S.; Attygalle, A.; Hazell, S.; Moschetta, M.; McLachlan, J.; Okines, A.; Banerjee, S. Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer Res. 2015, 35, 6713–6722.
  7. Boussios, S.; Karathanasi, A.; Zakynthinakis-Kyriakou, N.; Tsiouris, A.K.; Chatziantoniou, A.A.; Kanellos, F.S.; Tatsi, K. Ovarian carcinosarcoma: Current developments and future perspectives. Crit. Rev. Oncol. Hematol. 2019, 134, 46–55.
  8. McCluggage, W.G. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology 2011, 43, 420–432.
  9. Kurman, R.J.; Shih, I.M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum. Pathol. 2011, 42, 918–931.
  10. Koshiyama, M.; Matsumura, N.; Konishi, I. Recent concepts of ovarian carcinogenesis: Type I and type II. Biomed. Res. Int. 2014, 2014, 934261.
  11. Pavlidis, N.; Rassy, E.; Vermorken, J.B.; Assi, T.; Kattan, J.; Boussios, S.; Smith-Gagen, J. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021, 75, 102045.
  12. Boussios, S.; Moschetta, M.; Tatsi, K.; Tsiouris, A.K.; Pavlidis, N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. J. Adv. Res. 2018, 12, 1–9.
  13. Ghose, A.; Gullapalli, S.V.N.; Chohan, N.; Bolina, A.; Moschetta, M.; Rassy, E.; Boussios, S. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes. 2022, 10, 16.
  14. Toss, A.; Tomasello, C.; Razzaboni, E.; Contu, G.; Grandi, G.; Cagnacci, A.; Schilder, R.J.; Cortesi, L. Hereditary ovarian cancer: Not only BRCA 1 and 2 genes. Biomed. Res. Int. 2015, 2015, 341723.
  15. Biglia, N.; Sgandurra, P.; Bounous, V.E.; Maggiorotto, F.; Piva, E.; Pivetta, E.; Ponzone, R.; Pasini, B. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: Analysis of prognostic factors and survival. Ecancermedicalscience 2016, 10, 639.
  16. Shah, S.; Cheung, A.; Kutka, M.; Sheriff, M.; Boussios, S. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. Int. J. Environ. Res. Public. Health 2022, 19, 8113.
  17. Revythis, A.; Limbu, A.; Mikropoulos, C.; Ghose, A.; Sanchez, E.; Sheriff, M.; Boussios, S. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. Int. J. Environ. Res. Public. Health 2022, 19, 8577.
  18. Boussios, S.; Karathanasi, A.; Cooke, D.; Neille, C.; Sadauskaite, A.; Moschetta, M.; Zakynthinakis-Kyriakou, N.; Pavlidis, N. PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”. Diagnostics 2019, 9, 55.
  19. Tung, N.; Garber, J.E. PARP inhibition in breast cancer: Progress made and future hopes. NPJ Breast Cancer 2022, 8, 47.
  20. Boussios, S.; Rassy, E.; Shah, S.; Ioannidou, E.; Sheriff, M.; Pavlidis, N. Aberrations of DNA repair pathways in prostate cancer: A cornerstone of precision oncology. Expert. Opin. Ther. Targets 2021, 25, 329–333.
  21. Lancaster, J.M.; Powell, C.B.; Chen, L.M.; Richardson, D.L.; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 2015, 136, 3–7.
  22. Walker, J.L.; Powell, C.B.; Chen, L.M.; Carter, J.; Bae Jump, V.L.; Parker, L.P.; Borowsky, M.E.; Gibb, R.K. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015, 121, 2108–2120.
  23. Paluch-Shimon, S.; Cardoso, F.; Sessa, C.; Balmana, J.; Cardoso, M.J.; Gilbert, F.; Senkus, E.; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 2016, 27, v103–v110.
  24. Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome. Obstet. Gynecol. 2017, 130, 657–659.
  25. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet. Gynecol. 2014, 124, 1042–1054.
  26. Crosbie, E.J.; Ryan, N.A.J.; Arends, M.J.; Bosse, T.; Burn, J.; Cornes, J.M.; Crawford, R.; Eccles, D.; Frayling, I.M.; Ghaem-Maghami, S.; et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet. Med. 2019, 21, 2390–2400.
  27. US Preventive Services Task Force; Owens, D.K.; Davidson, K.W.; Krist, A.H.; Barry, M.J.; Cabana, M.; Caughey, A.B.; Doubeni, C.A.; Epling, J.W., Jr.; Kubik, M.; et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2019, 322, 652–665.
  28. Konstantinopoulos, P.A.; Norquist, B.; Lacchetti, C.; Armstrong, D.; Grisham, R.N.; Goodfellow, P.J.; Kohn, E.C.; Levine, D.A.; Liu, J.F.; Lu, K.H.; et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J. Clin. Oncol. 2020, 38, 1222–1245.
  29. Daly, M.B.; Pal, T.; Berry, M.P.; Buys, S.S.; Dickson, P.; Domchek, S.M.; Elkhanany, A.; Friedman, S.; Goggins, M.; Hutton, M.L.; et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021, 19, 77–102.
  30. Rebbeck, T.R.; Kauff, N.D.; Domchek, S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 2009, 101, 80–87.
  31. Iodice, S.; Barile, M.; Rotmensz, N.; Feroce, I.; Bonanni, B.; Radice, P.; Bernard, L.; Maisonneuve, P.; Gandini, S. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. Eur. J. Cancer 2010, 46, 2275–2284.
  32. Temkin, S.M.; Bergstrom, J.; Samimi, G.; Minasian, L. Ovarian Cancer Prevention in High-risk Women. Clin. Obstet. Gynecol. 2017, 60, 738–757.
  33. Ali, A.T. Towards Prevention of Ovarian Cancer. Curr. Cancer Drug Targets. 2018, 18, 522–537.
  34. Weissman, S.M.; Weiss, S.M.; Newlin, A.C. Genetic testing by cancer site: Ovary. Cancer J. 2012, 18, 320–327.
  35. Hunn, J.; Rodriguez, G.C. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 2012, 55, 3–23.
  36. Pal, T.; Permuth-Wey, J.; Betts, J.A.; Krischer, J.P.; Fiorica, J.; Arango, H.; LaPolla, J.; Hoffman, M.; Martino, M.A.; Wakeley, K.; et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104, 2807–2816.
  37. Pal, T.; Akbari, M.R.; Sun, P.; Lee, J.H.; Fulp, J.; Thompson, Z.; Coppola, D.; Nicosia, S.; Sellers, T.A.; McLaughlin, J.; et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br. J. Cancer 2012, 107, 1783–1790.
  38. Wooster, R.; Weber, B.L. Breast and ovarian cancer. N. Engl. J. Med. 2003, 348, 2339–2347.
  39. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 2000, 83, 1301–1308.
  40. Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25, 1329–1333.
  41. Walsh, T.; Casadei, S.; Lee, M.K.; Pennil, C.C.; Nord, A.S.; Thornton, A.M.; Roeb, W.; Agnew, K.J.; Stray, S.M.; Wickramanayake, A.; et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 2011, 108, 18032–18037.
  42. Ratajska, M.; Antoszewska, E.; Piskorz, A.; Brozek, I.; Borg, Å.; Kusmierek, H.; Biernat, W.; Limon, J. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res. Treat. 2012, 131, 89–97.
  43. Rafnar, T.; Gudbjartsson, D.F.; Sulem, P.; Jonasdottir, A.; Sigurdsson, A.; Jonasdottir, A.; Besenbacher, S.; Lundin, P.; Stacey, S.N.; Gudmundsson, J.; et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat. Genet. 2011, 43, 1104–1107.
  44. Yang, X.; Leslie, G.; Doroszuk, A.; Schneider, S.; Allen, J.; Decker, B.; Dunning, A.M.; Redman, J.; Scarth, J.; Plaskocinska, I.; et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J. Clin. Oncol. 2020, 38, 674–685.
  45. Meindl, A.; Hellebrand, H.; Wiek, C.; Erven, V.; Wappenschmidt, B.; Niederacher, D.; Freund, M.; Lichtner, P.; Hartmann, L.; Schaal, H.; et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 2010, 42, 410–414.
  46. Heikkinen, K.; Karppinen, S.M.; Soini, Y.; Mäkinen, M.; Winqvist, R. Mutation screening of Mre11 complex genes: Indication of RAD50 involvement in breast and ovarian cancer susceptibility. J. Med. Genet. 2003, 40, e131.
  47. Ramus, S.J.; Song, H.; Dicks, E.; Tyrer, J.P.; Rosenthal, A.N.; Intermaggio, M.P.; Fraser, L.; Gentry-Maharaj, A.; Hayward, J.; Philpott, S.; et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J. Natl. Cancer Inst. 2015, 107, djv214.
  48. Boussios, S.; Rassy, E.; Moschetta, M.; Ghose, A.; Adeleke, S.; Sanchez, E.; Sheriff, M.; Chargari, C.; Pavlidis, N. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers. 2022, 14, 3888.
  49. Backes, F.J.; Cohn, D.E. Lynch syndrome. Clin. Obstet. Gynecol. 2011, 54, 199–214.
  50. Grindedal, E.M.; Renkonen-Sinisalo, L.; Vasen, H.; Evans, G.; Sala, P.; Blanco, I.; Gronwald, J.; Apold, J.; Eccles, D.M.; Sánchez, A.A.; et al. Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds. J. Med. Genet. 2010, 47, 99–102.
  51. Piombino, C.; Cortesi, L.; Lambertini, M.; Punie, K.; Grandi, G.; Toss, A. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA. J. Oncol. 2020, 2020, 6384190.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Aruni Ghose
,
Anita Bolina
,
Ishika Mahajan
,
Syed Ahmer Raza
,
Miranda Clarke
,
Abhinanda Pal
,
Elisabet Sanchez
,
Kathrine Sofia Rallis
,
Stergios Boussios
View Times: 251
Revisions: 2 times (View History)
Update Date: 15 Sep 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback